Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 20 Nov 2026, 07:07 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- SGD 6.4T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | SGD 5.8B | SGD 53.10 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | SGD 25.5B | SGD 190.66 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | SGD 221B | SGD 50.13 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | SGD 7.2B | SGD 10.58 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 12.9 | SGD 153.8B | SGD 75.25 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | SGD 42.3B | SGD 104.20 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.4 | SGD 123.6B | SGD 61.68 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | SGD 21.7B | SGD 330.13 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | SGD 123.2B | SGD 1,190.91 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | SGD 30.7B | SGD 721.12 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | SGD 142.7B | SGD 59.41 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | SGD 350.9B | SGD 226.24 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | SGD 10.4B | SGD 159.96 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 29.6 | SGD 368.4B | SGD 195.04 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | SGD 170.3B | SGD 671.54 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | SGD 232B | SGD 133.97 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | SGD 202.5B | SGD 35.52 | 1.85% down | 15% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 40.5 | SGD 829.4B | SGD 344.55 | 2.04% down | 34% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | SGD 15.9B | SGD 19.13 | 1.00% down | 8% up | ||
| 20 | Eli LillyLLY · Health Care | 43.9 | SGD 1.55T | SGD 1,742.66 | 2.29% down | 33% up | ||
| 21 | GenmabGMAB · Health Care | 43.9 | SGD 40.8B | SGD 66.23 | 0.75% up | 70% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.3 | SGD 50.2B | SGD 87.34 | 1.38% down | 79% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | SGD 646.4B | SGD 365.71 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 48.9 | SGD 9.2B | SGD 83.81 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.2 | SGD 58.9B | SGD 515.53 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | SGD 9.6B | SGD 27.59 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | SGD 19.6B | SGD 304.97 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 70.9 | SGD 9.5B | SGD 120.64 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | SGD 58B | SGD 49.71 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 96.8 | SGD 12.6B | SGD 83.68 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | SGD 7.4B | SGD 370.09 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | SGD 422.3B | SGD 171.30 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | SGD 88.2B | SGD 27.61 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2898 SGD). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 20 Nov 2026, 07:07 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of SGD 6.4T as of 20 Nov 2026, 07:07 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.